Conference Reports for NATAP

Back

65th Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA Nov 7-11 2014     Summary from AASLD 2014 for Hepatitis C Boston 7-11 November 2014 - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (12/10/14)   HCV Health Economics, Cost Effectiveness   Health Economics/Cost Effectiveness: Cost-Effectiveness of Novel Hepatitis C Drug Regimens Among Treatment-Experienced U.S. Veterans - (12/02/14)   Health Economics/Cost Effectiveness: Direct Costs of Care for Hepatocellular Carcinoma in patients with Hepatitis C cirrhosis - (12/02/14)   Health Economics/Cost Effectiveness: AASLD: Health Economics/Cost-Effectiveness - (11/20/14)   Health Economics/Cost Effectiveness: Estimating the Number of Patients with Chronic Hepatitis C (HCV) Infection Meeting 'Highest' or 'High' Priority Treatment Criteria in the United States - (11/20/14)   Health Economics/Cost Effectiveness: Improving HCV care cascade outcomes in a community-based testing program by providing same day confirmatory testing and patient navigation - (11/20/14)   Health Economics/Cost Effectiveness: FIB4 Score and Gender Predict the Incidence of Hepatocellular Carcinoma (HCC) among Patients with Chronic Hepatitis C Virus (HCV) Infection: Chronic Hepatitis Cohort Study (CHeCS) - (11/17/14)   Health Economics/Cost Effectiveness: Increased All-cause Hospitalization among Hepatitis C Virus Infected Persons: the Chronic Hepatitis Cohort Study (CHeCS), 2006-2010 - (11/17/14)   Health Economics/Cost Effectiveness: The Use of All-Oral Regimens for Treatment of Chronic Hepatitis C Coupled with HCV Birth Cohort Screening is Highly Cost-Effective - (11/17/14)   Health Economics/Cost Effectiveness: Evaluation Of The Long-Term Health Outcomes Of Ledipasivir-Sofosbuvir (LDV/SOF) And Sofosbuvir-Based Regimens For Patients With Chronic Hepatitis C And Liver Cirrhosis Across Genotypes 1 To 4 - (11/17/14)   Health Economics/Cost Effectiveness: Treatment with Interferon- and Ribavirin-Free Regimens with Ledipasvir and Sofosbuvir Improves Patient-Reported Outcomes for Patients with Genotype 1 Chronic Hepatitis C: Results from the ION-1, 2 and 3 Clinical Trials - (11/17/14)   Health Economics/Cost Effectiveness: Evaluation of the Health Outcomes for Ledipasvir / Sofosbuvir in Early vs. Delayed Treatment According to the Fibrosis Stage of Patients with Chronic Hepatitis C Virus (HCV) Genotype 1 Infection: Results from a Decision-Analytic Markov Model....... "initiating earlier LDV/SOF treatment at F0-2 vs F3/4 reduced liver disease progression/sequalae by 66-82% & rests in lower lifetime costs by 14.3-15.9%" - (11/17/14)   Health Economics/Cost Effectiveness: A Decision-Analytic Markov Model to Evaluate the Health Outcomes of Ledipasvir/Sofosbuvir for Patients with Chronic Hepatitis C Genotype 1 Infection - (11/17/14)   Health Economics/Cost Effectiveness: LEDIPASVIR/SOFOSBUVIR SINGLE-TABLET REGIMEN FOR CHRONIC HEPATITS C (CHC) INFECTION: INSIGHTS FROM A WORK PRODUCTIVITY ECONOMIC MODEL - (11/17/14)   Health Economics/Cost Effectiveness: Projected Health and Economic Impact of Hepatitis C on the United States Medicare System From 2010 to 2024 - (11/17/14)         Hepatitis B   Phase 1a Safety and Pharmacokinetics of NVR 3-778, a Potential First-In-Class HBV Core Inhibitor - (01/16/15)   Phase II, dose ranging study of ARC-520, a siRNA-based therapeutic, in patients with chronic hepatitis B virus infection - (01/13/15)   Curing HBV....attacking cccDNA "Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease" - (01/12/15)   Phase 1a Safety and Pharmacokinetics of NVR 3-778, a Potential First-In-Class HBV Core Inhibitor - (01/12/15)   Novira Therapeutics Announces Presentation of Phase 1a - Safety and Pharmacokinetic Data for NVR 3-778 - (01/12/15)   The Antiviral Response to the Toll-Like Receptor 7 Agonist GS-9620 in Preclinical Models of Chronic Hepatitis B is Associated With an Intrahepatic Cytotoxic T Cell Transcriptional Signature - (01/12/15)   Cytokines Induced by a Toll-Like Receptor 7 Agonist Potently Inhibit HBV RNA, DNA, and Antigen Levels in Primary Human Hepatocytes - (01/12/15)   Timing of hepatocellular carcinoma (HCC) development and predictability of a modified PAGE-B risk score in Caucasian chronic hepatitis B (CHB) patients treated with entecavir (ETV) or tenofovir (TDF) - (01/09/15)   HBsAg Loss With Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a in Chronic Hepatitis B: Results of a Global Randomized Controlled Trial - (01/09/15)   Long-Term Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Infection Is Safe and Well Tolerated and Associated with Durable Virologic Response with No Detectable Resistance: 8 Year Results from Two Phase 3 Trials - (01/09/15)   No Detectable Resistance to Tenofovir Disoproxil Fumarate (TDF) in HBeAg+ and HBeAg- Patients With Chronic Hepatitis B (CHB) After Eight Years of Treatment - (01/09/15)   HBsAg Loss With Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a in Chronic Hepatitis B: Results of a Global Randomized Controlled Trial - (01/09/15)   The Antiviral Response to the Toll-Like Receptor 7 Agonist GS-9620 in Preclinical Models of Chronic Hepatitis B Is Associated With an Intrahepatic Cytotoxic T Cell Transcriptional Signature - (01/09/15)   Cytokines Induced by a Toll-Like Receptor 7 Agonist Potently Inhibit HBV RNA, DNA, and Antigen Levels in Primary Human Hepatocytes - (01/09/15)   The Safety and Efficacy of Entecavir and Tenofovir Combination Therapy for Chronic Hepatitis B in Patients with Previous Nucleos(t)ide Treatment Failure: Week 96 Results of the ENTEBE study - (01/09/15)   Entecavir reduces the incidence of hepatocellular carcinoma in patients with chronic hepatitis B - (01/09/15)   A Baseline Predictive Tool for Selecting HBeAg-Negative Chronic Hepatitis B Patients Who Have a High Probability of Achieving Sustained Immune Control with Peginterferon Alfa-2a - (01/09/15)   A Predictive Tool for Selecting HBeAg-Positive Chronic Hepatitis B Patients Who Have a High Probability of HBV DNA Suppression and HBeAg Seroconversion with Peginterferon Alfa-2a - (01/09/15)   HBeAg Levels Predict HBeAg Seroconversion During the Immune Clearance Phase of Chronic Hepatitis B in Patients Receiving Nucleot(s)ide Analogue Therapy - (01/09/15)   Loss of Immune Tolerance Is Associated With HBV Genotype-Specific Patterns of Accumulation of Basal Core Promoter and Precore Variants, Leading to Decline in HBeAg and HBsAg Levels - (01/09/15)   Entecavir Safety & Effectiveness in a National Cohort of Chronic Hepatitis B Patients in the USA - the ENUMERATE Study - (01/07/15)   Tenofovir Montherapy in Chronic Hepatitis B Patients with Genotypic Resistance to Previous Antiviral Therapy - a Cohort Study - (01/07/15)   Efficacy of Entecavir plus Tenofovir Combination Therapy for Chronic Hepatitis B Patients with Multi-Drug Resistant Strains (2) - (01/07/15)   Efficacy of Entecavir plus Tenofovir Combination Therapy for Chronic Hepatitis B Patients with Multi-Drug Resistant Strains - (01/07/15)   Entecavir plus adefovir or entecavir plus tenofovir for patients with chronic hepatitis B resistant to neucleot(s)ide analogues - (01/07/15)       Hepatitis C   ACH-3422, A Novel HCV NS5B RNA Polymerase Nucleotide Inhibitor, Demonstrates Improved Potency Over Sofosbuvir Against HCV Genotype-3 Replicons In Vitro - (02/19/15)   J&J New HCV Nucleotides - AL-335 & AL-516 - (01/23/15)   Pharmacokinetics of Cyclosporine and Tacrolimus, Following Coadministration with the Direct Acting Antiviral Combination, ABT-450/r, Ombitasvir and Dasabuvir, in Liver Transplant Patients with Genotype-1 HCV Infection - (12/22/14)   Simeprevir+Sofosbuvir at AASLD - (12/17/14)   Time to Viral Suppression [week 2/4] Is Not Related to Achievement of SVR12 in HCV GT1-infected Patients Treated With ABT-450/Ritonavir/Ombitasvir and Dasabuvir With or Without Ribavirin - (12/17/14)   Abbvie 3D in Depression-Bipolar/Opoid Replacement/Transplant/HIV Coinfection/African-Americans - (12/17/14)   Identification and Treatment of Multiple Subtypes of HCV Genotype 4 in the PEARL-I Study With Ombitasvir and ABT-450/r ± Ribavirin - (12/17/14)   TURQUOISE-II: Trends in Liver Fibrosis Testing, Hepatic Synthetic Function, and Platelet Counts at Baseline and 12 Weeks After Treatment With ABT-450/r/Ombitasvir and Dasabuvir With Ribavirin in HCV Genotype 1-Infected Patients With Cirrhosis - (12/17/14)   Early Improvement in the HepQuant® (HQ)-SHUNT Function Test during Treatment with Ledipasivir/Sofosbuvir in Liver Transplant Recipients with Allograft Fibrosis or Cirrhosis and Patients with Decompensated Cirrhosis who have not undergone Transplantation - (12/17/14)   Characteristics of HCV-Infected Patients With Cirrhosis Requiring Ribavirin Dose Reduction During Treatment With Direct-Acting Antivirals - (12/17/14)   Safety of ABT-450/r/Ombitasvir + Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients ≥65 Years of Age: Results From Phase 2 and 3 Trials - (12/15/14)   Resistance Analysis of Treatment-Experienced HCV Genotype 1-Infected Patients Re-treated With Sofosbuvir - (12/15/14)   The Pharmacokinetics of Ledipasvir, an HCV-Specific NS5A Inhibitor, in HCV-Uninfected Subjects With Severe Renal Impairment - (12/15/14)   SVR12 Rate of 96.2% in 209 HCV Genotype 1-infected Null Responders Treated With ABT-450/r/Ombitasvir and Dasabuvir With or Without Ribavirin - (12/15/14)   Safety of ABT-450/Ritonavir/Ombitasvir + Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients: Results From Phase 2 and 3 Trials - (12/15/14)   Baseline and Post-Baseline Resistance Analyses of Phase 2/3 Studies of Ledipasvir/Sofosbuvir ± RBV - (12/15/14)   Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin for the Treatment of Patients With Chronic HCV Genotype 1 Infection: An Analysis of the Phase 3 ION Trials - (12/15/14)   Performance and Cost -Effectiveness of Simeprevir and Sofosbuvir Based HCV treatment in Real World Clinical Practice - 2014 at Mt Sinai Hospital NY - (12/10/14)   Efficacy and Safety of Sofosbuvir and Simeprevir in Patients with Advanced HCV Cirrhosis - (12/10/14)   Interferon Ineligible subjects treated with Simeprevir in special population (Schizophrenic, severe major depression, severe bipolar and schizoaffective disorder) in genotype 1 subjects with Ribavirin Effecr; in naive chronic hepatitis C (CHC) genotype 1 subjects. An open label prospective clinical pilot study; INSPIRE C study - (12/10/14)   Single Center Experience with Simeprevir / Sofosbuvir Combination Therapy for Recurrent Hepatitis C Virus Infection in Liver Transplant Recipients - (12/10/14)   Multicenter Experience using Sofosbuvir and Simeprevir with/without Ribavirin to Treat HCV Genotype 1 after Liver Transplantation - (11/10/14)   Successful treatment of post liver transplant patients with genotype 1 hepatitis C virus with sofosbuvir and simeprevir - (12/10/14)   Post-Liver Transplant Treatment of Hepatitis C with a Combination of Sofosbuvir, Simeprevir +/- Ribavirin at a High Volume Academic Transplant Center - (12/10/14)   Time to Viral Suppression [week 2/4] Is Not Related to Achievement of SVR12 in HCV GT1-infected Patients Treated With ABT-450/Ritonavir/Ombitasvir and Dasabuvir With or Without Ribavirin - (12/09/14)   On-Treatment HCV RNA as a Predictor of Virologic Response in the Ledipasvir/Sofosbuvir Phase 3 Program for HCV Genotype 1 Infection: Analysis of the ION-1, ION-2, and ION-3 Studies - (12/09/14)   Evaluation of efficacy of sofosbuvirand simeprevir-based regimens in a real-life population of HCV patients with cirrhosis; data from the TRIO network - (12/09/14)   Efficacy of sofosbuvir and simeprevir-based regimens for HCV treatment-experienced GT1 patients in a real-life setting; data from the TRIO network - (12/09/14)   Rapid Normalization of Pro-Inflammatory Cytokine Levels During Potent Antiviral Therapy With Sofosbuvir Plus Ribavirin in Patients With Genotype 2 and 3 HCV Infection - (12/09/14)   97% Sustained Virologic Response in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection Receiving Sofosbuvir in Combination With Ribavirin for 12 Weeks: Results From a Phase 3 Multicenter Study - (12/09/14)   100% SVR12 in Japanese Patients With Chronic Genotype 1 Hepatitis C Virus Infection Receiving Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks: Results From a Multicenter Phase 3 Study - (12/09/14)   Concordance Between SVR4, SVR12, and SVR24 in Genotype 1 HCV-Infected Patients Who Received All Oral Fixed-Dose Combination Ledipasvir/Sofosbuvir With or Without Ribavirin in Phase 3 Clinical Trials - (12/05/14)   The Global Burden of Viremic HCV Infection - (12/05/14)   Disease Burden of Chronic Hepatitis C Virus (HCV) Infection in India - (12/05/14)   CLINICAL EFFICACY OF HIGHLY EFFECTIVE INTERFERON-FREE THERAPY IN PATIENTS WITH CHRONIC HCV INFECTION AND COMPENSATED ADVANCED HEPATIC FIBROSIS - Life Expectancy in Patients With Chronic HCV Infection and Cirrhosis Compared With a General Population - (12/03/14)   High Rates of SVR in Patients With Genotype 1 HCV Infection and Cirrhosis After Treatment With Ledipasvir/Sofosbuvir + Ribavirin or Ledipasvir/Sofosbuvir + GS-9669 for 8 Weeks - (12/03/14)   No Differences in the Efficacy of Fixed-Dose Combination Ledipasvir/Sofosbuvir in Patients According to Fibrosis Stage Determined by Liver Biopsy or Laboratory Biomarker in Phase 3 Clinical Trials - (12/03/14)   Urgent Treatment With Sofosbuvir Based Regimen For Hepatitis C Genotype 1 Patients With Severe Renal Insufficiency (GFR <30ml/min) - (12/03/14)   Safety, Antiviral Efficacy, and Pharmacokinetics of Sofosbuvir in Patients With Severe Renal Impairment - (12/03/14)   Interferon-Free Regimens of Ombitasvir and ABT-450/r With or Without Ribavirin in Patients With HCV Genotype 4 Infection: PEARL-I Study Results - (12/01/14)   Adherence to Prescribed Doses of ABT-450/r/Ombitasvir, Dasabuvir, and Ribavirin in the Phase 3 PEARL-II, PEARL-III, and PEARL-IV Trials - (12/01/14)   Preliminary results of a Daclatasvir (DCV) based treatment protocol (DCV+Sof, DCV+Simeprevir) in LT recipients with severe recurrent HCV - (12/01/14)   SVR12 Rate of 98.6% in 992 HCV Genotype 1b-Infected Patients Treated With ABT-450/r/Ombitasvir and Dasabuvir With or Without Ribavirin - (12/01/14)   HCV infection in opioid dependent pregnant women - (12/01/14)   Effects of Sustained Virological Response on the risk of liver transplant, hepatocellular carcinoma, death and re-infection: meta-analysis of 129 studies in 34,563 patients with Hepatitis C infection - (12/01/14)   Treatment of Hepatitis C Genotype 4 with Ledipasvir and Sofosbuvir for 12 weeks: Results of the SYNERGY Trial - (12/01/14)   Retreatment of Patients Who Failed Prior Sofosbuvir-Based Regimens With All Oral Fixed-Dose Combination Ledipasvir/Sofosbuvir Plus Ribavirin for 12 Weeks - (11/20/14)   Effectiveness of Hepatitis C Virus Testing for Persons Born during 1945-1965: Summary Results from Three Randomized Controlled Trials - (11/17/14)   Virologic Response Rates to All Oral Fixed-Dose Combination Ledipasvir/Sofosbuvir Regimens Are Similar in Patients With and Without Traditional Negative Predictive Factors in Phase 3 Clinical Trials - (11/17/14)   All-oral Dual Combination of Daclatasvir plus Asunaprevir Compared with Telaprevir plus Peginterferon Alfa/Ribavirin in Treatment-naive Japanese Patients Chronically infected with HCV Genotype 1b: Results from a Phase 3 Study - (11/17/14)   The Pharmacokinetics and Safety of the Direct Acting Antiviral Regimen of ABT-450/r, Ombitasvir with/without Dasabuvir in Subjects with Mild, Moderate and Severe Renal Impairment Compared to Subjects with Normal Renal Function - (11/14/14)   An Interferon-free Antiviral Regimen for HCV after Liver Transplantation Abbvie 3D - (11/14/14)   Pharmacokinetics and Safety of Pan-Genotypic, Direct Acting Protease Inhibitor, ABT-493, and NS5A Inhibitor, ABT-530, Following 3 Day Monotherapy in HCV Genotype-1 Infected Subjects With or Without Compensated Cirrhosis - (11/14/14)   A Next Generation HCV DAA Combination: Potent, Pangenotypic Inhibitors ABT-493 and ABT-530 With High Barriers to Resistance - (11/14/14)   Efficacy by Race or Geographic Region in HCV Genotype 1-Infected Patients Treated With ABT-450/Ritonavir/Ombitasvir and Dasabuvir With or Without Ribavirin - (11/14/14)   Drug-Drug Interaction Profile of the Fixed-Dose Combination Tablet Ledipasvir/Sofosbuvir - (11/14/14)   Mortality and progression to decompensated cirrhosis in chronic hepatitis C patients with liver biopsy confirmed fibrosis in the Chronic Hepatitis Cohort Study (CHeCS) - (11/14/14)   Mortality and progression to decompensated cirrhosis in chronic hepatitis C patients with liver biopsy confirmed fibrosis in the Chronic Hepatitis Cohort Study (CHeCS) - (11/13/14)   Interim Sustained Virologic Response (SVR), Safety And Tolerability Results Of 8-Week Treatment With ACH-3102 And Sofosbuvir In Chronic Hepatitis C (HCV), Genotype-1 (GT-1), Treatment-Naïve Patients: A Phase 2 "Proxy" Study - (11/13/14)   Antiviral Activity and Resistance Emergence: Combinations of the NS5B Nucleotide Inhibitor ACH-3422 with Other Antiviral Agents in Vitro - (11/13/14)   PEARL-IV Trial: Subgroup Analysis of Genotype 1a-infected Patients Treated With Dasabuvir Plus Ombitasvir/ABT-450/r With or Without Ribavirin - (11/13/14)   ABT-450/r/Ombitasvir + Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients With History of Depression or Bipolar Disorder: Pooled Analysis of Efficacy and Safety in Phase 3 Trials - (11/13/14)   ABT-450/r/Ombitasvir + Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Patients Receiving Stable Opioid Substitution Treatment: Pooled Analysis of Efficacy and Safety in Phase 2 and Phase 3 Trials - (11/13/14)   The Combination of Grazoprevir (MK-5172), an NS3 Inhibitor, and MK-8408, an NS5A Inhibitor, Presents a High Genetic Barrier to Resistance in HCV Genotypes 1a and 3a - (11/14/14)   MK-8408, a Potent and Selective NS5A Inhibitor With a High Genetic Barrier to Resistance and Activity Against HCV Genotypes 1-6 - (11/12/14)   Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial - (11/14/14)   Efficacy and safety of MK-5172 and MK-8742 ± RIBAVIRIN IN Hcv Gt1 Infected Patients with cirrhosis or previous null reSPonse: FINAL RESULTS OF the C-WORTHY Study (PARTS A AND B) - (11/12/14)   Efficacy and safety of MK-5172 and MK-8742 ± RIBAVIRIN IN Hcv Gt1 Infected Patients with cirrhosis or previous null reSPonse: FINAL RESULTS OF the C-WORTHY Study (PARTS A AND B) - (11/12/14)   Efficacy and safety of MK-5172 + MK-8742± ribavirin in HCV mono-infected and HIV/HCV co-infected treatment-naïve, non-cirrhotic patients with hCV gT1 infection: The C-WORTHY study (Final results, Parts A and B) - (11/12/14)   Ledipasvir/Sofosbuvir With Ribavirin for the Treatment of HCV in Patients With Decompensated Cirrhosis: Preliminary Results of a Prospective, Multicenter Study - (11/12/14)   HIGH SUSTAINED VIROLOGIC RESPONSE RATES IN LIVER TRANSPLANT RECIPIENTS WITH RECURRENT HCV GENOTYPE 1 INFECTION RECEIVING ABT-450/r/OMBITASVIR + DASABUVIR PLUS RIBAVIRIN CORAL-1 Study - (11/12/14)   A Phase I/IIa Study Assessing 7-Day Dosing of MK-3682 (formerly IDX21437)in Subjects Infected With Hepatitis C Virus (HCV) - (11/12/14)   Sofosbuvir and Ribavirin Therapy for the Treatment of HIV/HCV Coinfected Patients With HCV GT 1-4 Infection: The PHOTON-1 and -2 Trials - (11/12/14)   High Efficacy of Treatment With Sofosbuvir + GS-5816 ± Ribavirin for 12 Weeks in Treatment-Experienced Patients With Genotype 1 or 3 HCV Infection - (11/12/14)   Safety and Efficacy of LDV/SOF in African Americans: A Retrospective Analysis of Phase 3 Data - (11/12/14)   Gilead Announces Phase 2 Data for Investigational All-Oral Regimen of Sofosbuvir Plus GS-5816 for the Treatment of Chronic Hepatitis C - (11/12/14)   Hepatitis Debrief AASLD 2014 - (11/12/14)   TURQUOISE-I: 94% SVR12 in HCV/HIV-1 Co-infected Patients Treated With ABT-450/r/Ombitasvir and Dasabuvir and Ribavirin - (11/12/14)   (ELECTRON-2) High Efficacy of LDV/SOF Regimens for 12 Weeks for Patients With HCV Genotype 3 or 6 Infection - (11/12/14)   All-Oral, Fixed-Dose Combination Therapy With Daclatasvir/Asunaprevir/Beclabuvir for Non-Cirrhotic Patients With Chronic HCV Genotype 1 Infection: UNITY-1 Phase 3 SVR12 Results - (11/12/14)   Janssen at AASLD 2014 - (11/11/14)   Phase 3 UNITY Trials Demonstrate High Cure Rates for Investigational, All-Oral Daclatasvir TRIO Fixed-Dose Combination in Genotype 1 Hepatitis C Patients, Including Those with Cirrhosis - (11/11/14)   All-Oral Fixed-Dose Combination Therapy With Daclatasvir/Asunaprevir/Beclabuvir, ±Ribavirin, for Patients With Chronic HCV Genotype 1 Infection and Compensated Cirrhosis: UNITY-2 Phase 3 SVR12 Results - (11/11/14)   All-Oral 12-Week Combination Treatment With Daclatasvir and Sofosbuvir in Patients Infected With HCV Genotype 3: ALLY-3 Phase 3 Study - (11/11/14)   High Efficacy of LDV/SOF Regimens for 12 Weeks for Patients With HCV Genotype 3 or 6 Infection ELECTRON-2  - (11/11/14)   Ledipasvir/Sofosbuvir Fixed-Dose Combination Is Safe and Efficacious in Cirrhotic Patients Who Have Previously Failed Protease-Inhibitor Based Triple Therapy SIRIUS Trial  - (11/11/14)   Safety and Efficacy of New DAA---based Therapy for Hepatitis C Post---Transplant: Interval Results from the HCV---TARGET Longitudinal, Observational Study - (11/11/14)   ALLY Trial Demonstrates High Cure Rates for Investigational Daclatasvir and Sofosbuvir Combination among Genotype 3 Hepatitis C Patients - (11/11/14)   Achillion Reports 100% SVR12 in a Phase 2 Combination Study With ACH-3102 at the Liver Meeting 2014 (AASLD) - (11/11/14)   Ledipasvir/Sofosbuvir With Ribavirin for the Treatment of HCV in Patients With Post- Transplant Recurrence: Preliminary Results of a Prospective, Multicenter Study - (11/11/14)   An Integrated Safety and Efficacy Analysis of >500 Patients With Compensated Cirrhosis Treated With Ledipasvir/Sofosbuvir With or Without Ribavirin - (11/11/14)   Alios/J&J HCV Nucleotides Preclinical Data at AASLD - (11/11/14)   Once-Daily Sofosbuvir With GS-5816 for 8 Weeks With or Without Ribavirin in Patients With HCV Genotype 3 Without Cirrhosis Result in High Rates of SVR12: The ELECTRON-2 Study - (11/10/14)   Safety and Efficacy of Treatment with Sofosbuvir + GS-5816 ± Ribavirin for 8 or 12 Weeks in Treatment-Naïve Patients with Genotype 1-6 HCV Infection - (11/10/14)   C-SWIFT: Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Sofosbuvir in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection, With and Without Cirrhosis, for Durations of 4, 6, or 8 Weeks (Interim Results) - (11/10/14)   Safety and Efficacy of Sofosbuvir-Containing Regimens for Hepatitis C: Real-World Experience in a Diverse, Longitudinal Observational Cohort HCV-TARGET - (11/10/14)   Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network - Academic and community treatment of a real-world, heterogeneous population - (11/10/14)   Burden of Side Effects Associated with Treatment of Hepatitis C - (11/10/14)   Cerebral MR spectroscopy and patient reported mental health outcomes in hepatitis C genotype 1 naïve patients treated with ledipasvir and sofosbuvir (from Jules: these results found treatment with ledipasvir+sofosbuvir improved neuronal function) - (11/10/14)   L159F and V321A Sofosbuvir Treatment-Emergent HCV NS5B Substitutions - (11/10/14)   C-SWIFT: Grazoprevir (MK-5172) + Elbasvir (MK-8472) + Sofosbuvir in Treatment-Naïve Patients with Hepatitis C Virus Genotype 1 Infection, With and Without Cirrhosis, for Durations of 4, 6 or 8 Weeks (Interim Results) - (11/10/14)   INTEGRATED EFFICACY ANALYSIS OF FOUR PHASE 3 STUDIES IN HCV GENOTYPE 1A-INFECTED PATIENTS TREATED WITH ABT-450/R/OMBITASVIR AND DASABUVIR WITH OR WITHOUT RIBAVIRIN - (11/10/14)   TURQUOISE-II: REGIMENS OF ABT-450/r/OMBITASVIR AND DASABUVIR WITH RIBAVIRIN ACHIEVE HIGH SVR12 RATES IN HCV GENOTYPE 1-INFECTED PATIENTS WITH CIRRHOSIS, REGARDLESS OF BASELINE CHARACTERISTICS - (11/10/14)   Use of Ledipasvir/Sofosbuvir Fixed Dose Combination for Treatment of HCV Genotype-1 Infection in Patients Coinfected with HIV - Eradicate Study - (11/10/14)